Search Results

Longhorn Vaccines and Diagnostics, a One Health company developing vaccines and diagnostic tools for global public health and zoonosis concerns, will present three abstracts at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2024.

Longhorn Vaccines and Diagnostics presented positive data from three key studies of its infectious disease franchise at the European Congress of Clinical Microbiology and Infectious Diseases 2024.

Longhorn Vaccines and Diagnostics Congress all day April 2-4, 2024 on a mice study that examined LHNVD-110, a novel, unconjugated single peptide vaccine comprised of multiple epitopes to broadly target human and influenza viruses.

Longhorn Vaccines and Diagnostics today presented new data from an animal study of LHNVD-301, the company’s lead tuberculosis vaccine candidate.

Longhorn Vaccines and Diagnostics LLC, a One Health company developing vaccines and diagnostic tools for global public health and zoonosis concerns, announced today new data supporting the potential benefits of LHNVD-105, the company’s universal influenza vaccine candidate.

Longhorn Vaccines and Diagnostics, a One Health company developing vaccines and diagnostic tools for global public health and zoonosis concerns, will present new data from an animal study of LHNVD-301, the company’s tuberculosis vaccine candidate, at The Union World Conference on Lung Health 2023.

Longhorn Vaccines and Diagnostics, a One Health company developing vaccines and diagnostic tools for global public health and zoonosis concerns, presented new data from an animal study indicating the durability and broad strain coverage of LHNVD-105, the company’s universal influenza vaccine candidate.

Longhorn Vaccines and Diagnostics to Present Durability Data of Peptide-Based Vaccine LHNVD-201 for Covid-19 and Influenza Co-Infections at 17th Vaccine Congress.

Longhorn Vaccines and Diagnostics LLC announced today new data validating the company’s core diagnostic product, PrimeStore® Molecular Transport Medium (MTM), and its potential to increase access to Mycobacterium tuberculosis (TB) testing for children in remote and underserved areas and reduce time to diagnosis and initiation of life-saving treatment.

Longhorn Vaccines and Diagnostics announced today new data from the USDA National Veterinary Services Laboratory validating the company’s core diagnostic product, PrimeStore® Molecular Transport Medium (PS-MTM), and its potential to inactivate highly consequential livestock and poultry viruses to support safer and more effective diagnostic testing.